% Expired Patents = 50.0

Forward Citations = 0

Loading Chart...

3 inventors (with patents filed for the assignee):

Thomas MacAllister (3 out of 14 patents)

Sven M Jacobson (2 out of 2 patents)

Zujiang Yu (1 out of 1 patent)

4 patents: Sort by Forward Citations

1. 12274687 - Methods for treating ascites (2025-04-14),

2. 12268661 - Methods of treating ascites (2025-04-08),

3. 11020392 - Use of trimetazidine as a hepatoprotective medicine in prevention and treatment of liver diseases and conditions (2021-06-01),

4. 10946011 - Stable oral liquid formulation of trimetazidine (2021-03-16),

Company Overview

Martin Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for various medical conditions. With a commitment to advancing healthcare, Martin Pharmaceuticals is engaged in the research of novel drug formulations aimed at enhancing patient outcomes. The company's portfolio includes products designed to treat chronic illnesses and improve the quality of life for patients worldwide. By leveraging cutting-edge technology and a dedicated team of professionals, Martin Pharmaceuticals is poised to make significant contributions to the field of medicine and pharmaceuticals.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#1,393 in New York, NY

#3,678 in New York

#60,597 in US

New York, NY, United States of America

Martin Pharmaceuticals, Inc.

Forward Citations = 0

3 inventors:

Thomas MacAllister (3 out of 14 patents)

Sven M Jacobson (2 out of 2 patents)

Zujiang Yu (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Martin Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/martin-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]